Re: Enzalutamide in metastatic prostate cancer before chemotherapy

摘要

PREVAIL is a multinational, double-blind, randomised trial comparing enzalutamide, which is an oral androgen receptor inhibitor, and placebo. Beer et al. demonstrated that enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) had significant clinical benefits including better rates of radiograpftic progression-free survival (rPFS) and overall survival (OS).